Want to see PHR full AI Analyst Report?
PHR Stock Chart & Stats
$10.22
$0.42(4.29%)
At close: 4:00 PM EDT
$10.22
$0.42(4.29%)
Day’s Range― - ―
52-Week Range$7.77 - $32.76
Previous CloseN/A
Volume895.77K
Average Volume (3M)942.63K
Market Cap
$663.24M
Enterprise Value$589.25
Total Cash (Recent Filing)$74.71M
Total Debt (Recent Filing)$92.56M
Price to Earnings (P/E)70.5
Beta1.07
Next Earnings
Sep 09, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding61,811,890
10 Day Avg. Volume692,785
30 Day Avg. Volume942,626
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)2.38
Price to Sales (P/S)1.67
P/FCF Ratio11.85
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$14.00Price Target Upside36.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)0.4
Revenue Forecast (FY)$515.15M
Bulls Say, Bears Say
Bulls Say
Cash GenerationPhreesia’s recent TTM operating cash flow and robust free cash flow generation demonstrate durable cash conversion from operations. High FCF (about 86% of net income) provides flexibility to fund investments, delever, or absorb lumpy payments programs, improving long‑term financial resilience.
Recurring Revenue & Network ScaleA subscription/usage model plus life‑sciences engagements gives Phreesia diversified recurring revenue. Growing AHSC and higher revenue per client support predictable cash flows and upsell opportunities, creating durable customer lock‑in and network value for long‑term revenue stability.
Profitability Trajectory & LiquidityPhreesia has shifted to sustained profitability with rising adjusted EBITDA and reiterated guidance, while strengthening liquidity via a multi‑year revolver and larger securitization. This combination supports execution of strategy and cushions the business against cyclical shocks over the coming months.
Bears Say
Subscription Revenue WeaknessSequential subscription declines hit the core recurring provider revenue that underpins long‑term predictability. Management’s pricing moderation to preserve retention may blunt near‑term revenue per client and shows fragility in organic uptake, risking pressure on unit economics if prolonged.
Network Solutions Demand VariabilityGreater variability and lower client commitments in Network Solutions reduce visibility into future revenue and complicate capacity planning. For a business relying on predictable campaign volumes, persistent variability can erode revenue growth consistency and make margin planning harder over multiple quarters.
Acquisition‑Driven Payment Growth & Funding RiskA meaningful portion of Payment Solutions growth stems from a recent acquisition, which raises questions about organic scaling and integration risk. Coupled with increased use of securitization and revolver funding to support payment volume, this heightens exposure to credit and funding dynamics that could pressure margins.
Phreesia News
PHR FAQ
What was Phreesia’s price range in the past 12 months?
Phreesia lowest stock price was $7.77 and its highest was $32.76 in the past 12 months.
What is Phreesia’s market cap?
Phreesia’s market cap is $663.24M.
When is Phreesia’s upcoming earnings report date?
Phreesia’s upcoming earnings report date is Sep 09, 2026 which is in 34 days.
How were Phreesia’s earnings last quarter?
Phreesia released its earnings results on May 27, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.011 by $0.039.
Is Phreesia overvalued?
According to Wall Street analysts Phreesia’s price is currently Undervalued.
Does Phreesia pay dividends?
Phreesia does not currently pay dividends.
What is Phreesia’s EPS estimate?
Phreesia’s EPS estimate is 0.09.
How many shares outstanding does Phreesia have?
Phreesia has 61,811,890 shares outstanding.
What happened to Phreesia’s price movement after its last earnings report?
Phreesia reported an EPS of $0.05 in its last earnings report, beating expectations of $0.011. Following the earnings report the stock price went up 3.505%.
Which hedge fund is a major shareholder of Phreesia?
Currently, no hedge funds are holding shares in PHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phreesia Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (36.99% Upside)
$14.00 (36.99% Upside)
Blogger Sentiment
Neutral
PHR Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
66.37%
Trailing 12-Months
Company Description
Phreesia
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.
PHR Company Deck
PHR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear operating and financial positives: solid top-line growth (+13% YoY), strong adjusted EBITDA improvement (+~46% YoY) and a return to net income, improved operating and free cash flow, enhanced liquidity via refinancing and a larger securitization facility for Access One, and maintained full-year guidance. Headwinds included a sequential decline in subscription revenue, higher variability and lower-than-expected client commitments in Network Solutions for the back half of the year, and some dependence of Payment Solutions growth on the recent Access One acquisition. On balance, the positive operational and financial momentum, maintaining guidance, and strategic financing and product initiatives outweigh the listed challenges.View all PHR earnings summariesPHR Revenue Breakdown
45.91% Subscription and related services
27.90% Payment processing fees
26.19% Network solutions
PHR Stock 12 Month Forecast
Average Price Target
$14.00
▲(36.99% Upside)
Technical Analysis
Ownership Overview
20.63% Insiders
18.24% Mutual Funds
2.22% Other Institutional Investors
46.88% Public Companies and
Individual Investors